|Videos|January 18, 2016
- NSCLC (Issue 10)
- Volume 10
- Issue 10
Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer
Author(s)Geoffrey R. Oxnard, MD
Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.
Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.
Articles in this issue
almost 10 years ago
Research Team Challenges Plant-Derived Molecule for the Treatment of NSCLCalmost 10 years ago
Combining Immunotherapy With Anti-VEGF Agents Rigorously Explored in NSCLCalmost 10 years ago
Lung Cancer Research Shows Distinct Genomic Differences in Younger PatientsRelated Content
Advertisement
